{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-031405","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2023-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.119380+00:00","generated_at":"2026-06-10T23:56:14.419933+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"X4 Pharma submits NDA to FDA for mavorixafor in WHIM syndrome","bullets":["Submission supported by positive Phase 3 4WHIM trial results; met primary and key secondary endpoints.","Requested priority review; if granted, FDA review period would be six months from acceptance.","Mavorixafor is an oral once-daily candidate for WHIM syndrome, a rare primary immunodeficiency in patients 12+.","No treatment-related serious adverse events or discontinuations for safety in the Phase 3 trial.","CEO Paula Ragan calls it a significant milestone; could be first approved U.S. product for WHIM syndrome."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-031405","json":"https://secwatch.observer/filing/0001628280-23-031405.json","markdown":"https://secwatch.observer/filing/0001628280-23-031405.md","text":"https://secwatch.observer/filing/0001628280-23-031405.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023031405/0001628280-23-031405-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023031405/xfor-20230905.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:56:14.419933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}